NCT03240016View on ClinicalTrials.gov

Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 8, 2018

Primary Completion Date

June 23, 2023

Study Completion Date

June 23, 2023

Conditions
Urothelial Carcinoma
Interventions
DRUG

Pembrolizumab

200mg IV D1

DRUG

Abraxane

100mg/m\^2 D1 and D8

Trial Locations (1)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT03240016 - Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer | Biotech Hunter | Biotech Hunter